Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis

of 49% (P.001 vs placebo group). The change in maximum CIMT for the 12 carotid sites was �0.0014 (95% CI, �0.0041 to 0.0014) mm/y for the rosuvastatin group vs 0.0131 (95% CI, 0.0087-0.0174) mm/y for the placebo group (P.001). The change in maximum CIMT for the rosuvastatin group was �0.0038 (95% CI, �0.0064 to �0.0013) mm/y for the common carotid artery sites (P.001), �0.0040 (95% CI, �0.0090 to 0.0010) mm/y for the carotid bulb sites (P.001), and 0.0039 (95% CI, �0.0009 to 0.0088) mm/y for the internal carotid artery sites (P=.02). The change in mean CIMT for the rosuvastatin group for the common carotid artery sites was 0.0004 (95% CI, �0.0011 to 0.0019) mm/y (P.001). AllP values are vs placebo group. Overall, rosuvastatin was well tolerated with infrequent serious adverse cardiovascular events (6 participants [0.86%] had 8 events [1.1%] over 2 years). Conclusions In middle-aged adults with an FRS of less than 10% and evidence of subclinical atherosclerosis, rosuvastatin resulted in statistically significant reductions in the rate of progression of maximum CIMT over 2 years vs placebo. Rosuvastatin did not induce disease regression. Larger, longer-term trials are needed to determine the clinical implications of these findings. Trial Registration clinicaltrials.gov Identifier: NCT00225589